|
Discovery | Pre-Clinical | Phase I | Phase II | Phase III | Manufacturing |
Regulatory | EB Programs
我们理解新兴生物技术公司在将下一代新药推向市场时所面临的挑战。这就是我们推出新兴生物技术（EB）拨款计划的原因，我们在世界不同地区定期实施这些计划。这些计划让拨款接收者免费获得产品和服务。
现在就申请我们的新兴生物科技资助项目！
我们正在举办第8届新兴生物科技资助项目，该项目对台湾地区的生物科技公司开放，可帮助您加快走进临床的步伐。
现在申请就有机会赢得免费的默克工艺解决方案部门的产品，以及工艺开发服务：
现在就申请我们的新兴生物科技资助项目！
我们正在举办第7届新兴生物科技资助项目，该项目对中国大陆地区的生物科技公司开放，可帮助您加快走进临床的步伐。
现在申请就有机会赢得免费的默克工艺解决方案部门的产品，以及工艺开发服务：
注册与规则获得者
技术和服务领域25,000欧元至100,000欧元奖励的获得者，以表彰其加速医药进入市场 查看新闻发布
获得者
技术和服务领域人民币280,000元拨款的获得者
获得者
NGM被授予价值8.9万美元的产品和服务。 查看公告
如果您想收到关于我们下一个新兴生物技术拨款计划的信息， 请留下您的详细信息，以便我们联系您。
Unlock your molecule's potential
2018 Advance Biotech Grant ProgramBringing your molecule to market. As part of our commitment to meet the needs of the life science community, we’ve developed several programs that recognize stand-out emerging biotech companies. These programs are designed to support biotech start-ups and medium sized companies in solving their current bioprocess development challenges to bring the next generation of molecules to market.
Learn more about the advantages to work with one source on your mAb, linker/ payload supplies and conjugation services.
Review the current dynamics in the RNA therapeutics/vaccines market with a focus on process development and manufacturing strategies.
Learn more on points to consider for successful tech transfers with a focus on cGMP training requirements.
Establishing an open dialog within the biotech community....
A report from the The Economist Intelligence Unit sponsored by Merck.
This paper, which incorporates the results of a survey of 254 pharmaceutical executives from around the world and a range of interviews with industry experts, explores in detail global pharmaceutical companies' growth strategies and their plans for managing the associated risks.
Research. Development. Production.
We are a leading supplier to the global Life Science industry: solutions and services for research, development and production of biotechnology and pharmaceutical drug therapies.
